NCT07107932 A Registry： Siltartoxatug Injection for Tetanus Prophylaxis Following Injury
| NCT ID | NCT07107932 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Zhuhai Trinomab Pharmaceutical Co., Ltd. |
| Condition | Tetanus |
| Study Type | OBSERVATIONAL |
| Enrollment | 10,000 participants |
| Start Date | 2025-07-31 |
| Primary Completion | 2029-03-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 10,000 participants in total. It began in 2025-07-31 with a primary completion date of 2029-03-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The injury and wound conditions of the enrolled patients will be documented. A follow-up at 90 days post-administration will determine the clinical outcome of tetanus prophylaxis, specifically whether tetanus occurred. The registry will also employ selective safety data collection to record adverse reactions and serious adverse events following Siltartoxatug adminstration.
Eligibility Criteria
Inclusion Criteria: * 1.Having received or will receive Siltartoxatug for tetanus prophylaxis following injury; * 2\. Provided signed informed consent by themselves or their legal representatives. Exclusion Criteria: * None
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07107932 clinical trial?
This trial is open to participants of all sexes, studying Tetanus. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07107932 currently recruiting?
Yes, NCT07107932 is actively recruiting participants. Contact the research team at sammi.qu@trinomab.com for enrollment information.
Where is the NCT07107932 trial being conducted?
This trial is being conducted at Shantou, China, Xiangyun, China, Shaoxing, China, Zhoushan, China.
Who is sponsoring the NCT07107932 clinical trial?
NCT07107932 is sponsored by Zhuhai Trinomab Pharmaceutical Co., Ltd.. The trial plans to enroll 10,000 participants.